Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    Biosimilars and Oral Agents Lead New Approvals in the Cancer Setting
    U.S. Food and Drug Administration (FDA)

    Biosimilars and Oral Agents Lead New Approvals in the Cancer Setting

    A majority of the U.S. Food and Drug Administration (FDA) approvals for cancer agents in the latter part of 2018 represented second and third approvals for new indications in other disease sites. Many were given expedited approval, but with that comes the potential that the incidence of adverse events may be underrepresented because fewer patients received the agents in a clinical trial setting. 

    December 18, 2018
    FDA Approves Romiplostim for Pediatric Patients With Immune Thrombocytopenia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Romiplostim for Pediatric Patients With Immune Thrombocytopenia

    On December 14, 2018, the U.S. Food and Drug Administration (FDA) approved romiplostim for pediatric patients one year of age and older with immune thrombocytopenia for at least six months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

    December 14, 2018
    San Antonio Breast Cancer Symposium

    Glutathione Plays a Role in Treatment-Related CINV

    Chemotherapy-induced nausea and vomiting (CINV) can negatively affect nutritional intake, ability to work, and treatment adherence. Research suggests that younger age and female gender are the strongest predictors of CINV, but those may not be the only factors, particularly for delayed nausea, according to research findings presented at the San Antonio Breast Cancer Symposium on December 5, 2018.

    December 13, 2018
    Manage Afatinib’s Adverse Events to Keep Patients on Treatment
    Adverse events

    Manage Afatinib’s Adverse Events to Keep Patients on Treatment

    Ongoing therapy with afatinib—an oral, irreversible ErbB family blocker—for as long as it is effective and tolerable is considered first-line treatment for metastatic non-small cell lung cancer in patients with EGFR mutations. In their article in the October 2018 issue of the Clinical Journal of Oncology Nursing, Edwards, Adan, Lalla, Lacouture, O’Brien, and Sequist discussed the most common adverse events (AEs) associated with afatinib and their real-life experiences managing them in clinical practice to keep patients on therapy.

    December 11, 2018
    San Antonio Breast Cancer Symposium

    Study Identifies Novel Triplet Therapy for HR+/HER2+ Breast Cancer

    Researchers from the University of Colorado Denver Young Women Breast Cancer Translational Program in Aurora identified a potential triplet combination for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (HER2+) breast cancer: HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib, and selective estrogen receptor blocker fulvestrant. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Time to Treatment Discontinuation Shorter in Patients Who Receive First-Line Palbociclib

    Current treatment guidelines recommend sequential hormone therapy for patients with hormone receptor-positive (HR+) metastatic breast cancer who are not in visceral crisis and whose disease is not refractory to endocrine treatment. Second-line fulvestrant monotherapy is a treatment option for patients in whom disease progresses after first-line palbociclib. Researchers used real-world data to evaluate the time to treatment discontinuation (TTD) of second-line fulvestrant in patients with HR+ human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer who did (n = 88) and did not (n = 100) receive first-line palbociclib and found it was shorter in patients who received palbociclib. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    U.S. Spending on Antineoplastics Nearly Doubles From 2011–2016
    Treatments

    U.S. Spending on Antineoplastics Nearly Doubles From 2011–2016

    Dollars spent on cancer drugs increased from $26.8 billion in 2011 to $42.1 billion in 2016, according to the results of a study reported in the Journal of Oncology Practice.

    December 05, 2018
    American Society of Hematology Annual Meeting

    Majority of Real-World Patients With DLBCL Are Eligible for CAR T-Cell Therapy

    Patients with diffuse large B-cell lymphoma (DLBCL) often experience long-term survival after initial anthracycline-containing therapy; however, relapse leads to poor outcomes. Some patients with relapsed or refractory disease may receive additional chemoimmunotherapy followed by hematopoietic cell transplantation (HCT), but as many as 50% of patients cannot undergo HCT because of lack of response to chemoimmunotherapy or comorbidities. Chimeric antigen receptor (CAR) T-cell therapy may be an option for those patients, but real-world data on CAR T-cell therapy for DLBCL are limited.

    December 01, 2018
    American Society of Hematology Annual Meeting

    Risk Assessment Tool Predicts Survival in Older Patients Undergoing HCT

    Older patients are at increased risk for complications and death following allogeneic hematopoietic cell transplantation (alloHCT), and traditional transplant-specific prognostic indices such as the hematopoietic cell transplant comorbidity index (HCT-CI) may not adequately predict survival. Researchers found that routine pretransplant assessments by interdisciplinary clinical providers, including advanced practice providers and nursing staff, may uncover additional geriatric deficits. Richard J. Lin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York, NY, discussed the findings at the ASH Annual Meeting on December 1, 2018.

    December 01, 2018
    American Society of Hematology Annual Meeting

    CBT May Improve Response to Subsequent Treatment in Heavily Pretreated Patients With HL

    Patients with relapsed or refractory Hodgkin lymphoma (HL) after checkpoint blockade therapy (CBT) have limited options. However, researchers found that CBT may impact response to subsequent therapies. Nicole A. Carreau, MD, of New York University Langone Health in New York City, discussed the findings at the ASH Annual Meeting on December 1, 2018.

    December 01, 2018
    FDA Approves Rituximab-ABBS as Biosimilar to Rituximab for Non-Hodgkin’s Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Rituximab-ABBS as Biosimilar to Rituximab for Non-Hodgkin Lymphoma

    On November 28, 2018, the U.S. Food and Drug Administration (FDA) approved rituximab-abbs as the first biosimilar to rituximab for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

    November 28, 2018
    Researchers Win Nobel Prize for Work in Cancer Immunotherapy
    Cancer research

    Researchers Win Nobel Prize for Work in Cancer Immunotherapy

    Two researchers whose discoveries led to the development of the first cancer immunotherapy treatments, immune checkpoint inhibitors, were awarded the 2018 Nobel Prize in Medicine in October.

    November 28, 2018
    FDA Approves Gilteritinib for Relapsed, Refractory AML With a FLT3 Mutation
    U.S. Food and Drug Administration (FDA)

    FDA Approves Gilteritinib for Relapsed, Refractory AML With an FLT3 Mutation

    On November 28, 2018, the U.S. Food and Drug Administration (FDA) approved gilteritinib for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

    November 28, 2018
    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions

    On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.

    November 27, 2018
    Chemotherapy Is Still a Staple in Treatment Plans. Here’s a Fresh Look at a Familiar Treatment Option
    Treatments

    Chemotherapy Is Still a Staple in Treatment Plans. Here’s a Fresh Look at a Familiar Treatment Option

    Despite all of the new drugs approved in recent years—particularly immunotherapies, oral agents, and biosimilars—that have forced nurses to consider many novel approaches to patient care, the importance of chemotherapy in cancer treatment has remained a constant. In a field where it feels like no two days are the same and new drugs emerge on a rolling basis, chemotherapy continues to be a staple in cancer treatment plans and safety and administration principles remain constant. 

    November 26, 2018
    FDA Approves Glasdegib for AML
    U.S. Food and Drug Administration (FDA)

    FDA Approves Glasdegib for AML in Adults Aged 75 or Older or Who Have Comorbidities

    On November 21, 2018, the U.S. Food and Drug Administration (FDA) approved glasdegib in combination with low-dose cytarabine, for newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy.

    November 26, 2018
    FDA Approves Brentuximab Vedotin for Previously Untreated sALCL and CD30-Expressing PTCL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brentuximab Vedotin for Previously Untreated sALCL and CD30-Expressing PTCL

    On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA approval for previously untreated PTCL including sALCL.

    November 20, 2018
    The Integrative Oncology Nurse: New Role for a New Era in Cancer Care
    Complementary therapy

    The Integrative Oncology Nurse: New Role for a New Era in Cancer Care

    When patients or loved ones receive a cancer diagnosis, they often experience fear, worry, and a desire to do everything possible to increase the chance of survival. It is also a pivotal time for patients to assess their well-being and lifestyle and make positive changes. For many, complementary therapies become part of their cancer care journey. Internationally, 40% of patients with cancer have reported using complementary therapies to address cancer-related symptoms, improve the effectiveness of conventional treatments, and provide hope.

    November 15, 2018
    Recent NSAID Use May Improve Ovarian Cancer Survival
    Research

    Recent NSAID Use May Improve Ovarian Cancer Survival

    Researchers have found that use of nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to improve survival for patients with epithelial ovarian cancer. The study results were published in Lancet Oncology.

    November 14, 2018
    FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma

    On November 9, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with hepatocellular carcinoma who have been previously treated with sorafenib.

    November 13, 2018
    An Oncology Nursing Overview of Biosimilars
    Clinical practice

    An Oncology Nursing Overview of Biosimilars

    Since the first biosimilar agent was approved by the U.S. Food and Drug Administration (FDA) in 2015, patients and providers have had concerns about the implications for their care and practice, respectively. Because 6 of the 12 biosimilar drugs currently approved in the United States have indications for oncology practice, oncology nurses have a responsibility to understand the drugs’ safety and efficacy for the patients in their care.

    November 13, 2018
    ONS Tackles Oral Chemotherapy Complexities
    Oral adherence

    ONS Tackles Oral Chemotherapy Complexities

    To ensure that patients and providers are equipped with the latest, most up-to-date knowledge and resources, ONS routinely works with patient advocacy groups, subject matter experts, and other provider organizations to develop and refine critical information for clinical practice. Following safety standards and meeting patient education requirements are critical to successful oral chemotherapy practice.

    November 06, 2018
    FDA Approves Lorlatinib for Second, Third-Line Treatment of ALK-Positive Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lorlatinib for Second, Third-Line Treatment of ALK-Positive Metastatic NSCLC

    On November 2, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (Lorbrena) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

    November 05, 2018
    JADPRO Live

    Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving Carboplatin

    In 2017, the National Comprehensive Cancer Network and American Society of Clinical Oncology released new antiemetic guidelines that recommended adding an NK1 receptor antagonist (RA) to standard 5-hydroxytryptamine RA plus dexamethasone upfront for patients receiving carboplatin area under the curve (AUC) ≥ 4. In January 2018, the Centers for Medicare and Medicaid Services instituted a new quality outcome measure, OP-35, which assesses “potentially avoidable” acute care for nausea, vomiting, or eight other common chemotherapy-related toxicities (anemia, dehydration, diarrhea, fever, neutropenia, pain, pneumonia, and sepsis).

    November 02, 2018
    Which RN is Competent in Chemotherapy Administration?
    Chemotherapy

    Which RN Is Competent in Chemotherapy Administration?

    Which RN is Competent in Chemotherapy Administration?

    1. One that took a chemotherapy course online 2 years ago and recently completed their annual education.
    2. One that witnessed a chemotherapy competent nurse administer chemotherapy orally and parenterally on five separate occasions
    3. One that took a chemotherapy course offered by her hospital and completed an administration checklist with a chemo competent nurse          
    4. One who works on a unit that cares for patients receiving chemotherapy
    November 01, 2018
    FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC

    On October 30, 2018, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

    October 31, 2018
    FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

    On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a poly (ADP-ribose) polymerase inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

    October 16, 2018
    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab
    Clinical practice

    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab

    Monoclonal antibody cancer treatments such as rituximab have a high risk for hypersensitivity reactions from cytokine release syndrome. The symptoms, which can range from mild to life threatening, result from tumor antigen-expressing cells releasing cytokines (e.g., tumor necrosis factor, interleukin, interferon) into the blood as they are destroyed. Symptoms include fever, chills, rigors, rash, headache, hypotension, shortness of breath, bronchospasm, nausea, vomiting, and abdominal pain.

    October 09, 2018
    Ketogenic Diet May Overcome Drug Resistance With PI3K Inhibitors
    Treatments

    Ketogenic Diet May Overcome Drug Resistance With PI3K Inhibitors

    Researchers have shown in mouse models that using PI3K inhibitor targeted therapy along with a ketogenic diet may help prevent or overcome the drug resistance that can eventually occur. The findings were reported in Nature.

    October 03, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cemiplimab-RWLC for Metastatic or Locally Advanced CSCC

    On September 28, 2018, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

    October 02, 2018
    FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL or SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL or SLL

    On September 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.

    September 25, 2018
    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care
    U.S. Food and Drug Administration (FDA)

    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care

    As researchers learn more about how combination therapy combats drug resistance and lessens the changes of tumor evasion of the immune system, immune checkpoint inhibitors are receiving approval for a broader range of indications. However, recent U.S. Food and Drug Administration (FDA) approvals have centered around hematologic malignancies and the emergence of two new biosimilars. 

    September 25, 2018
    Older Patients Respond Better to Checkpoint Inhibitors for Melanoma
    Melanoma

    Older Patients Respond Better to Checkpoint Inhibitors for Melanoma

    Patients aged 62 and older are more likely to respond to immune checkpoint inhibitors for melanoma, such as pembrolizumab, according to findings from a study published in Clinical Cancer Research. A follow-up study showed that it may be because of age-related changes in the immune cells in melanoma tumors.

    September 19, 2018
    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer
    Treatments

    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer

    Lung cancer is the second most common cancer in both men and women (after skin cancer) and is the leading cause of cancer death among both men and women. Histology has become an important determinant in choosing therapy for various types of cancer, including non-small cell lung cancer (NSCLC). Currently, biomarker testing is the standard of care in lung cancer; with biomarker testing, patients likely to respond to targeted therapy can be identified. As the number of targeted agents continues to increase, so does the demand for continued biomarker testing and adequate tumor tissue samples.

    September 14, 2018
    FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukemia

    On September 13, 2018, the U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox-tdfk (Lumoxit), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

    September 13, 2018
    NINR Study Identifies Genes for Fatigue in Cancer Treatment
    Genetics & genomics

    NINR Study Identifies Genes for Fatigue in Cancer Treatment

    Radiation therapy can be an incredibly draining form of treatment for patients with cancer. Side effects such as fatigue can be debilitating for many before, during, and after treatment. Because symptom management is a crucial component to cancer care and central role of oncology nursing, ensuring that patients are able to mitigate their symptoms and side effects can help improve their quality of life. Recently, a team at the National Institute of Nursing Research (NINR) identified certain genes associated with fatigue in men being treated for prostate cancer.

    August 29, 2018
    FDA Grants Approval for Pembrolizumab in Combination with Chemotherapy for First-line Treatment of Metastatic Nonsquamous NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Approval for Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC

    On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.

    August 20, 2018
    FDA Grants Nivolumab Accelerated Approval for Third-line Treatment of Metastatic SCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Nivolumab Accelerated Approval for Third-Line Treatment of Metastatic SCLC

    On August 16, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.

    August 20, 2018
    FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

    On August 16, 2018, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma.

    August 16, 2018
    How APRNs Can Support Patients During Oral Agent Treatment
    Advanced practice nursing (APN)

    How APRNs Can Support Patients During Oral Agent Treatment

    Oral agents offer many patient benefits, one of which is the freedom to take the medication at home, allowing them to keep their daily routine and gain additional time and independence they would have spent traveling to the clinic for treatment. However, with that freedom comes additional patient responsibilities, and preparation from advanced practice RNs (APRNs) is necessary to ensure patients can self-manage symptoms and adhere to administration regimens. Research shows that patients experience severe symptoms on oral agents that may cause them to miss as many as one-third of the prescribed doses. How can APRNs empower patients to adhere to the treatment plan and ensure safe symptom self-management at home? 

    August 16, 2018
    An Oncology Nurse’s Guide to Targeted Therapy
    Targeted therapy

    An Oncology Nurse’s Guide to Targeted Therapy

    Whereas chemotherapy induces apoptosis by interfering with cell division of both cancerous and healthy cells, targeted therapy exploits targets, proteins, enzymes, or genes specific to malignant cells through a variety of mechanisms of action, which helps prevent drug resistance. The agents work by either inhibiting angiogenesis, blocking chemical signals that tell cells to divide or carry out normal function, or delivering toxic substances to a cell. 

    August 14, 2018
    TNM Gets an Upgrade in Eighth Edition Staging Guidelines
    Clinical practice guidelines

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines

    Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

    August 09, 2018
    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome
    U.S. Food and Drug Administration (FDA)

    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome

    On August 8, 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc (Poteligeo) for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

    August 08, 2018
    Men May Have Greater Survival Benefit From Immune Checkpoint Inhibitors
    Immunotherapy

    Men May Have Greater Survival Benefit From Immune Checkpoint Inhibitors

    Researchers have found a significant difference in overall survival in men versus women receiving immune checkpoint inhibitors for advanced cancers. The findings from the systematic review and meta-analysis were reported in Lancet Oncology.

    August 08, 2018
    FDA Approves Ivosidenib for Relapsed or Refractory AML
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ivosidenib for Relapsed or Refractory AML

    On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

    July 20, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Ipilimumab for Certain Metastatic Colorectal Cancers

    On July 10, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to ipilimumab for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

    July 12, 2018
    FDA Approves Encorafenib and Binimetinib in Combination
    U.S. Food and Drug Administration (FDA)

    FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma With BRAF Mutations

    On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved encorafenib and binimetinib (Braftovi and Mektovi) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

    June 28, 2018
    Latest FDA Cancer Treatment Approvals Trend Toward New Indications
    U.S. Food and Drug Administration (FDA)

    Latest FDA Cancer Treatment Approvals Trend Toward New Indications

    What is unique about the most recent U.S. Food and Drug Administration (FDA) approvals in the oncology/hematology area is that almost all are for new indications of existing agents as opposed to new agents. This is not surprising because many of the agents target specific bioassays or tumor markers instead of a specific disease site. Oncology nurses need to be aware of the changes because treatments that they have become accustomed to giving for one indication may soon be given for others as well.

    June 28, 2018
    Monitoring Document for Monoclonal Antibodies
    Oncology nurse influence

    Oncology Nurse Develops Monitoring Document for Monoclonal Antibodies

    It’s a rote but important phrase: Necessity is the mother of invention. When a need presents itself, developing novel, inventive solutions can lead to important change. But inventive change doesn’t have to come on a massive scale: small inventions can still have a big impact.

    June 22, 2018
    ONS Congress

    Drug Offers Extended Adjuvant Treatment Option for HER2+ Metastatic Breast Cancer

    An estimated 266,120 new cases of invasive breast cancer and 40,920 related deaths will occur in the United States in 2018. Patients with distant disease have a poorer five-year relative survival rate (26.9%) compared with localized (98.9%) and regional (85.2%) disease. HER2+ breast cancer accounts for approximately 20%–25% of all breast cancer diagnoses, and this type of breast cancer is more common in younger women, decreasing in frequency with age across all stages.

    June 21, 2018
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Current page 3
    • Page 4
    • Page 5
    • Page 6
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲